Nouscom's Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to 'Intercept' Cancer in Subjects with Lynch Syndrome pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Nouscom announces leading publication revealing an immune mechanism of action driving anti-tumor activity of adenovirus vectored vaccines and anti-PD1 immunotherapy Research paper published in Science Translational Medicine by Nouscom and the Armenise-Harvard Laboratory of Immunoregulation at IIGM led by Luigia.
Nouscom today announced encouraging new translational data obtained from the ongoing Phase 1 trial evaluating NOUS-209. The data were presented yesterday